Understanding the healthy brain aging process is key to uncovering the mechanisms leading to pathological age-related neurodegeneration, including progression to Alzheimer's disease (AD). Here, we report the first deep whole genome sequencing study aiming to identify variants that are associated specifically to healthy brain aging defined on both clinical and neuropathological level, thus tacking the issue of pathological heterogeneity that often underlies a clinical AD diagnosis. We studied samples from the VITA brain bank and followed an extreme phenotypic ends study design comparing neuropathologically "healthy" aging individuals above 80 years of age with pure AD patients of the same age. Focusing on the extreme ends of the phenotypic distribution, and potentially functional variants, we discover a single variant (rs10149146) carried by 53.6% of the "healthy" brain elderly individuals in our study (15/28 individuals) and none of the 12 AD cases. This variant lies on the autophagy and cell cycle associated TECPR2 gene. Autophagy dysfunction has been previously implicated in multiple progressive neurodegenerative diseases. An additional nonsynonymous variant on the CINP gene (encoding a cell-cycle checkpoint protein) is also found in 46% of healthy controls and absent from all the AD cases. TECPR2 and CINP appear to be "partner" genes in terms of regulation and their associated transcription factors have been previously implicated in AD and neurodegeneration. Our study is the first to support the hypothesis that a TECPR2 non-synonymous variant carries a significant neuroprotective effect pointing to key molecules for the involvement of autophagy and cell cycle control in protection from neurodegeneration.
INTRODUCTION
As life expectancy increases and fertility rates fall, the world population is aging 1 A recent meta-analysis of 74,046 individuals confirmed eight and reported 11 newly associated AD susceptibility loci [4] [5] [6] [7] A gene-based approach of the same dataset uncovered two more susceptibility loci 8 . However, the abovementioned genome-wide association studies implicate variants that account only for a small proportion of the estimated heritability of AD, leaving the substantial rest of the proportion unidentified. Attention has been turned to rare variants present in less than 1% of the population under the "common disease-multiple rare variants" hypothesis, currently amenable to large-scale analysis via next generation sequencing technologies 9 . In fact, low-frequency missense variants have been found to confer either strong protection or elevated risk of AD and cognitive decline [10] [11] [12] .
On the other hand, longevity and healthy aging show a heritability of 20-50% 13, 14 . One might anticipate that genetic factors which increase the risk of common complex neurodegenerative diseases such as AD would negatively affect life-span and be less common among long-lived people as compared to younger aged individuals 15 . Conversely, the genetic contribution to longevity is hypothesized to be greatest at the oldest ages 16 ; however, not much is known regarding how genetic factors might influence healthy brain aging and cognition maintenance 17 .The TOMM40-APOE region on chromosome 19q13.32 remains the most significantly associated locus with both longevity and cognition 16, 18 . Looking into variants that have been previously implicated in longevity, we also picked up the association to rs4420638 marker near APOC1 gene which was previously implicated in a case-control GWAS conducted on 763 German centenarians and nonagenarians, and 1,085 controls (mean age 60 years) 16 (P value =2.00e-04, see Supplementary results for details).
To examine variants most likely to have a neuroprotective effect, we filtered for unique variants in at least 10 of the 28 neuropathologically "normal" controls, in our study but absent in all 12 cases. This resulted in 6,984 variants (Table S1) Table 2 . Besides gene-coding variants, we also explored the potential involvement of variants in exons of non-coding RNAs. Again, as a filtering step, we focused on variants that are common in at least 10 "healthy" aged controls and absent from all cases.
We identified eight such prioritized variants as shown in Table 3 .
We proceeded to perform Sanger sequencing in order to confirm the whole genome sequencing results. Sanger sequencing was not able to confirm all of the whole genome sequencing called variants. We were thus able to further narrow down our search for genes that carry non-synonymous variants in at least 10 controls and none of the cases to only two 
DISCUSSION
In the past two decades, evidence has accumulated in favour of the existence of genetic factors associated with AD-related pathology, via either GWAS studies with single-marker associations alone or by combining GWAS data with neuroimaging data, leading to the identification of 20 AD susceptibility loci [4] [5] [6] [7] [8] [24] [25] [26] . However, very little is known about the protective genetic influences against neurodegeneration and in favour of healthy brain aging.
Genetic influences of cognitive abilities and aging in old age are prominent and approximately 50% of this variance may be attributed to multiple genetic variants with small effects 27 . Candidate gene studies have highlighted the potential roles of genes such as BDNF, COMT and DTNBP1 in either cognitive ability and normal function (such as learning and memory) or cognitive decline; yet associations for other genes remain inconclusive 28 .
In this study, we applied a genome-wide sequencing analysis aiming at the identification of variants and genes that may be important for healthy aging, in an effort to characterise factors for the prevention of pathological age-related neurodegeneration. Importantly, based on detailed neuropathological evaluations, we were able to define two extremes of the phenotypic distribution of brain aging; old age individuals with minimal signs of neurodegeneration versus pure AD. Demonstrating the power of our approach, despite the small sample size, we were able to pick up the neuroprotective effect of the APOE2 variant (p=0.02). We identified two non-synonymous exonic variants in two genes that are present in 53.6% ad 46% respectively of 28 healthy aging controls and absent from all 12 pure AD cases that we studied. The associated genes TECPR2 and CINP appear to be "partner" genes in terms of regulation 23 and are associated with autophagy 29 and cell-cycle control 30 respectively. Notably, the transcription factors we found associated with these two genes have also previously been implicated in neurodegeneration; a POU2F1 (OCT1) intronic variant has been associated with AD and the POU2F1 gene was found to be down-regulated in the hippocampus of AD brains but not healthy controls 31 , USF has been found to interact with the Alzheimer amyloid beta-protein precursor gene 32 , The beta-amyloid peptide mediates synapse loss through the CREB signaling pathway, while YY1 is an activator of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1), a prerequisite for the generation of betaamyloid peptides, the principle constituents of senile plaques in the brains of patients with Alzheimer's disease (AD) 33 41 . Increased N-MYC and C-MYC expression in reactive astrocytes may also play a role in reactive astrocytosis in human neurodegenerative disorders 42 .
Despite the relatively low number of cases examined, our strict criteria and by focusing on extreme ends of the phenotypic distribution of neuropathology-related variants, we were able to identify an autophagy and cell-cycle related gene to be associated with healthy aging specifically lacking pathological protein depositions and vascular lesions, which is unusual in the aging brain 19, 20 . The implicated genes warrant further investigation and highlight the key role of autophagy and cell-cycle control in protecting from neurodegeneration. This is the first study to specifically attempt to find genetic variants that promote healthy brain aging based on neuropathological evaluations of post-mortem samples. Our approach contrasts those based only on clinical criteria but also neuropathology-based studies, which do not apply a holistic approach by examining the whole spectrum of proteinopathies and other brain lesions.
In an aging world and with no existing cure for dementias, the need to increase our understanding of their etiology is imperative, Elucidating the physiological pathways that drive the shift from healthy brain aging to neurodegeneration, will lead to the identification of targets for improved therapies and prevention strategies for AD and related neurodegenerative disorders.
METHODS

Subjects
We selected cases from the longitudinal aging transdanubian VITA study 19 
Whole genome sequencing (WGS), processing of raw sequences and variant calling
DNA was extracted from fresh-frozen cerebellum and frontal cortex tissue. Whole genome sequencing was performed by the Biomedical Sequencing Facility at CeMM, using Illumina
HiSeq 2000 machines with a read length was 2x100 base pairs in the paired-end configuration. The sequencing reads were aligned to the b37 reference genome with EpsteinBarr Virus sequence (BROAD 1000 Genomes GRCH37) using BWA-MEM aligner, and 49 was used for gene ontology analysis.
Sanger Sequencing
All controls carrying prioritized variants were sequenced by the Sanger custom sequencing method, using the BigDye Terminator v.3.1 chemistry on an ABI 3730XL genetic analyzer.
Sequencing was performed on both DNA strands and sequences were both aligned and visually observed by at least two independent researchers.
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